Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07037459 · ClinicalTrials.gov registry record · Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
A Phase 3 study of Obesity and Heart Failure With Preserved Ejection Fraction, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 5,056
- Enrollment target
- 20
- Study locations
NCT07037459: Recruiting Phase 3 study of Obesity and Heart Failure With Preserved Ejection Fraction, sponsored by Amgen.
NCT07037459 is a Phase 3 study of Obesity and Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by Amgen. The registered enrollment target is 5,056 participants, above the 814-participant average among 1,053 other Obesity trials with a reported enrollment target (521% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07037459, a Phase 3 study of Obesity and Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 5,056 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.
Primary Outcome
Heart Failure events include: hospitalization for HF or urgent HF visits.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maridebart cafraglutide
Study Locations (20)
California
- National Heart Institute - Beverly Hills
- Valley Clinical Trials, LLC dba Flourish Research - Covina
- National Institute of Clinical Research - Huntington Beach
- 310 Clinical Research - Inglewood
- Radin Cardiovascular Medical Group - Newport Beach
- Valley Clinical Trials - Northridge
- University of California Irvine - Orange
- Empire Clinical Research - Pomona
- San Diego Cardiac Center - San Diego
- NorthBay Clinical Research LLC - Santa Rosa
- Manshadi Heart Institute - Stockton
Alabama
- University of Alabama at Birmingham - Birmingham
- SEC Clinical Research - Dothan
- Eastern Shore Research Institute - Fairhope
- Heart Center Research LLC - Huntsville
Arizona
- HonorHealth - Phoenix
- Medical Advancement Centers of Arizona - Phoenix
- Pima Heart and Vascular Clinical Research - Tucson
- Yuma Clinical Trials - Yuma
Arkansas
- Arkansas Cardiology - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,056 participants |
| Start Date | 2025-06-25 |
| Est. Completion | 2030-09-29 |
| Phase | Phase 3 |
What NCT07037459 shows while recruiting
NCT07037459 is an interventional study that assigns participants to a tested intervention. Its 5,056 participants enrollment target places it among the larger protocols in the corpus, above the 814-participant average among 1,053 other Obesity trials with a reported enrollment target (521% higher).
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07037459 names 20 study sites across 4 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT07037459 about?
NCT07037459 is a clinical study titled "Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity". This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fract...
What is the current status of trial NCT07037459?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,056 participants. The study started on 2025-06-25. Estimated completion is 2030-09-29.
What conditions does trial NCT07037459 study?
This clinical trial studies the following conditions: Obesity, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction.
What interventions are being tested in trial NCT07037459?
The interventions under investigation include: Placebo (DRUG), Maridebart cafraglutide (DRUG).
Who is sponsoring clinical trial NCT07037459?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07037459 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07037459's enrollment target sits among peer trials
5,056 18th of 1053 higher than 1,036 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06292078 · 5,076 participants · NA
Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)
- NCT05018611 · 5,100 participants · NA
Digital Limited Interaction Efficacy Trial of LifeSkills Mobile to Reduce HIV Incidence in YTW
- NCT05701358 · 5,100 participants · NA
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
- NCT04743362 · 5,010 participants
A Study of Noninvasive Methods to Evaluate Skin and Mucosal Conditions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI